Latest Biotech Startup Funding Rounds
Financing for drug discovery, therapeutics and biological technologies, with the development context behind each round.
- Rounds
- 477 Jan 1 – Oct 25, 2026
- Disclosed funding
- $20.2B 403 disclosed amounts
- Median round
- $20M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
 4D PathCompany profile Digital biomarkers designed to predict cancer treatment response from routine biopsy images. Digital biomarkers designed to predict cancer treatment response from routine biopsy images. | Undisclosed | StrategicUndisclosed | Biotech, Healthtech | United States | Investors Undisclosed | |
| N NavidenceCompany profile Provides AI-native platform with standardized computable definitions of diseases and outcomes for real-world evidence research Provides AI-native platform with standardized computable definitions of diseases and outcomes for real-world evidence research | Undisclosed | StrategicUndisclosed | Biotech, Healthtech | United States | Investors | |
| LB Latus Bio, Inc.Company profile Engineers scalable AAV gene therapies for CNS and rare diseases including Huntington's disease and CLN2 Engineers scalable AAV gene therapies for CNS and rare diseases including Huntington's disease and CLN2 | $97M | Series A | Biotech | United States | Investors | |
| E EnteroBiotixCompany profile Develops full-spectrum microbiome therapeutics for gastrointestinal diseases including IBS Develops full-spectrum microbiome therapeutics for gastrointestinal diseases including IBS | £19M | Series B | Biotech | United Kingdom | Investors | |
| GP General ProximityCompany profile Develops induced proximity medicines targeting undruggable proteins across oncology and cardiometabolic disease Develops induced proximity medicines targeting undruggable proteins across oncology and cardiometabolic disease | $20M | StrategicUndisclosed | Biotech | United States | Investors | |
| OB Oberland BiotechCompany profile Develops and trades nutritional supplements and food products internationally Develops and trades nutritional supplements and food products internationally | CHF 2.5M | Seed | Biotech | Switzerland | Investors | |
| M Decodes cellular networks to advance human health | $20M | Undisclosed | Biotech | Sweden | Investors | |
| IH Develops technology and services for clinical research. | $77M | Series CSeries C+ | Biotech, Healthtech | United States | Investors | |
| A AxoftCompany profile Develops implantable Brain-Computer Interfaces (iBCIs) for neurological disorders Develops implantable Brain-Computer Interfaces (iBCIs) for neurological disorders | $55M | Series A | Biotech, Healthtech | United States | Investors | |
| VB Vivacta BiotechnologyCompany profile Develops in vivo CAR-T cell therapies for cancer and autoimmune diseases Develops in vivo CAR-T cell therapies for cancer and autoimmune diseases | $50M | Series A+Series A | Biotech | China | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · From Jan 1, 2026
- 1RA Capital Management
Estuary Biotherapeutics, Circle Pharma, Inc., Solstice Oncology
23rounds3led - 2Janus Henderson Investors
Star Therapeutics, OMass Therapeutics, Soufflé Therapeutics
15rounds1led - 3Eli Lilly and Company
BigHat Biosciences, Circle Pharma, Inc., Moonwalk Biosciences
15rounds0led - 4ARCH Venture Partners
Soufflé Therapeutics, Encoded Therapeutics Inc., Moonwalk Biosciences
14rounds0led - 5OrbiMed
Star Therapeutics, Leal Therapeutics, Accro Bioscience
11rounds1led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.